Could a Freeze-Dried vaccine shield all ages from hib?
NCT ID NCT06621654
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new freeze-dried version of the Haemophilus influenzae type b (Hib) vaccine to see if it is safe and triggers a protective immune response. The study includes healthy people aged 2 months, 6-11 months, 1-5 years, and 18-59 years, with younger groups enrolled only after older groups show initial safety. Participants receive one or more doses of the vaccine, and researchers monitor for side effects and immune markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine
- What this could lead to
- If successful, this could lead to a more stable, freeze-dried Hib vaccine that protects infants and adults from serious bacterial infections like meningitis and pneumonia.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the vaccine may not produce a strong immune response or may cause unexpected side effects. Further studies are needed before it could be widely used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILUS INFLUENZAE TYPE B INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiulongpo District Center for Disease Control and Prevention
Chongqing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.